Related Experiment Video
Updated: Jun 4, 2025
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
2.8K
Optimal glucocorticoid therapy in lupus nephritis
Gabriel Figueroa-Parra1,2, Mario Bautista-Vargas2, Erika Navarro-Mendoza2
1Rheumatology Service, Department of Internal Medicine, University Hospital "Dr José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México.
Summary
Glucocorticoids are key for lupus nephritis (LN) but optimal dosing is unclear. Research is needed to balance efficacy with side effects for better patient outcomes in this severe kidney disease.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Lupus nephritis (LN) affects up to 51.7% of systemic lupus erythematosus patients, increasing mortality and end-stage kidney disease risk.
- Glucocorticoids have been a primary treatment for LN due to anti-inflammatory effects, though optimal strategies are debated.
- Understanding glucocorticoid mechanisms and long-term risks is crucial for managing LN effectively.
Purpose of the Study:
- To provide an in-depth analysis of glucocorticoid therapy in lupus nephritis.
- To review the historical use, evolving dosing strategies, and mechanistic pathways of glucocorticoids in LN.
- To explore current evidence on efficacy, safety, and alternative treatment approaches.
Main Methods:
- Comprehensive literature review of glucocorticoid therapy in lupus nephritis.
- Analysis of historical treatment trends and current dosing strategies (e.g., IV pulse, oral).
- Examination of genomic and non-genomic mechanisms of glucocorticoid action.
Main Results:
- Shift from high-dose to combined immunosuppressant and lower-dose glucocorticoid regimens to mitigate adverse effects.
- Long-term glucocorticoid use is associated with significant risks including infection, osteoporosis, hyperglycemia, and cardiovascular disease.
- Evidence supports various dosing strategies, with promising but understudied alternatives like low-dose and glucocorticoid-free regimens.
Conclusions:
- Glucocorticoids remain a cornerstone of lupus nephritis management despite challenges.
- Further research is essential to optimize glucocorticoid regimens, refine tapering, and develop safer therapeutic combinations.
- Balancing glucocorticoid efficacy with toxicity is critical for improving patient outcomes in LN.
More Related Videos
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
217
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
217
01:29Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119